|
Gene: RFX7 |
Gene summary for RFX7 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RFX7 | Gene ID | 64864 |
Gene name | regulatory factor X7 | |
Gene Alias | RFXDC2 | |
Cytomap | 15q21.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q2KHR2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64864 | RFX7 | CCI_1 | Human | Cervix | CC | 8.97e-04 | 1.12e+00 | 0.528 |
64864 | RFX7 | CCI_2 | Human | Cervix | CC | 4.57e-15 | 1.27e+00 | 0.5249 |
64864 | RFX7 | CCI_3 | Human | Cervix | CC | 1.51e-16 | 6.92e-01 | 0.516 |
64864 | RFX7 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.09e-13 | -5.60e-01 | 0.0155 |
64864 | RFX7 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.18e-03 | -4.85e-01 | -0.1808 |
64864 | RFX7 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.45e-09 | -6.91e-01 | -0.1207 |
64864 | RFX7 | HTA11_696_2000001011 | Human | Colorectum | AD | 8.33e-09 | -4.04e-01 | -0.1464 |
64864 | RFX7 | HTA11_866_2000001011 | Human | Colorectum | AD | 6.63e-06 | -3.73e-01 | -0.1001 |
64864 | RFX7 | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.13e-03 | -5.88e-01 | -0.2061 |
64864 | RFX7 | HTA11_5216_2000001011 | Human | Colorectum | SER | 3.62e-02 | -6.03e-01 | -0.1462 |
64864 | RFX7 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.35e-09 | -5.38e-01 | 0.096 |
64864 | RFX7 | HTA11_8622_2000001021 | Human | Colorectum | SER | 4.23e-04 | -7.08e-01 | 0.0528 |
64864 | RFX7 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.87e-10 | -3.99e-01 | 0.0674 |
64864 | RFX7 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.33e-05 | -4.71e-01 | 0.0588 |
64864 | RFX7 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 7.05e-04 | -2.76e-01 | 0.294 |
64864 | RFX7 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 3.27e-02 | 5.53e-01 | 0.3487 |
64864 | RFX7 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.88e-09 | -4.07e-01 | 0.3859 |
64864 | RFX7 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.06e-04 | -5.71e-01 | 0.2585 |
64864 | RFX7 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.62e-11 | -4.33e-01 | 0.3005 |
64864 | RFX7 | F007 | Human | Colorectum | FAP | 5.81e-04 | -1.76e-01 | 0.1176 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RFX7 | SNV | Missense_Mutation | c.1655C>G | p.Pro552Arg | p.P552R | Q2KHR2 | protein_coding | deleterious_low_confidence(0.04) | benign(0.015) | TCGA-BR-7901-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
RFX7 | SNV | Missense_Mutation | rs369466675 | c.1522N>T | p.Arg508Cys | p.R508C | Q2KHR2 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.446) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR |
RFX7 | SNV | Missense_Mutation | c.2771N>T | p.Arg924Met | p.R924M | Q2KHR2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-CG-4306-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
RFX7 | SNV | Missense_Mutation | novel | c.169N>G | p.Met57Val | p.M57V | Q2KHR2 | protein_coding | deleterious(0.02) | possibly_damaging(0.771) | TCGA-CG-5723-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
RFX7 | SNV | Missense_Mutation | novel | c.3589N>T | p.Pro1197Ser | p.P1197S | Q2KHR2 | protein_coding | tolerated(0.46) | benign(0.005) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
RFX7 | insertion | Frame_Shift_Ins | novel | c.3454_3455insA | p.Ile1152AsnfsTer8 | p.I1152Nfs*8 | Q2KHR2 | protein_coding | TCGA-BR-A4QL-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | CR | ||
RFX7 | deletion | Frame_Shift_Del | novel | c.2754delN | p.Ser919AlafsTer14 | p.S919Afs*14 | Q2KHR2 | protein_coding | TCGA-CG-4460-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PD | ||
RFX7 | deletion | Frame_Shift_Del | c.3454delA | p.Ile1152Ter | p.I1152* | Q2KHR2 | protein_coding | TCGA-RD-A8NB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |||
RFX7 | SNV | Missense_Mutation | novel | c.326N>T | p.Glu109Val | p.E109V | Q2KHR2 | protein_coding | deleterious(0.04) | probably_damaging(0.941) | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
RFX7 | insertion | In_Frame_Ins | novel | c.2813_2814insCCAAAATGAGTG | p.Tyr938_His939insGlnAsnGluCys | p.Y938_H939insQNEC | Q2KHR2 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |